ClinicalTrials.gg
CompletedNCT00907296STARTTUpdated Sep 22, 2022Results posted

Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing

A Phase 2 interventional study of Romosozumab and Placebo in Fracture Healing, sponsored by Amgen. Completed at 103 sites in 23 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-09-22.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
402
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The primary objective of this study is to investigate the effect of romosozumab compared with placebo on time to radiographic healing of fresh tibial diaphyseal fractures (fractures in the midsection of the shinbone).

02

Conditions studied

  • Fracture Healing

Keywords

  • Fracture Healing
  • Tibial Diaphyseal Fracture
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Skeletally mature adults, age 18 to 85 years with radiographically closed growth plates
  • Fresh unilateral closed or Gustilo type I or type II open tibial fracture
  • Definitive fracture fixation with reamed (closed and open fractures) or unreamed (open fractures only) intramedullary nailing

Exclusion criteria

Exclusion Criteria:

  • Major polytrauma or significant axial trauma
  • Associated lower extremity fracture that will delay subject's ability to bear weight beyond the normal time expected for a tibial shaft fracture
  • Use of bone grafts at the time of fracture fixation
  • Pathological fracture or metabolic or bone disease
  • History of symptomatic spinal stenosis or facial nerve paralysis
  • within the last 5 years
  • Evidence of the following (currently or within the past 5 years): elevated transaminases, significantly impaired renal function, current hyper- or hypocalcaemia
  • Use of agents affecting bone metabolism
  • Subject refuses to use appropriate methods of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
402 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.

    Drug: Placebo

  • Experimental
    Romosozumab 70 mg: 2 Doses

    Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.

    Biological: Romosozumab

  • Experimental
    Romosozumab 70 mg: 3 Doses

    Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.

    Biological: Romosozumab

  • Experimental
    Romosozumab 70 mg: 4 Doses

    Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.

    Biological: Romosozumab

  • Experimental
    Romosozumab 140 mg: 2 Doses

    Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.

    Biological: Romosozumab

  • Experimental
    Romosozumab 140 mg: 3 Doses

    Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.

    Biological: Romosozumab

  • Experimental
    Romosozumab 140 mg: 4 Doses

    Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.

    Biological: Romosozumab

  • Experimental
    Romosozumab 210 mg: 2 Doses

    Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.

    Biological: Romosozumab

  • Experimental
    Romosozumab 210 mg: 3 Doses

    Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.

    Biological: Romosozumab

  • Experimental
    Romosozumab 210 mg: 4 Doses

    Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.

    Biological: Romosozumab

Interventions

  • BiologicalRomosozumab

    Administered by subcutaneous injection

    Also known as: AMG 785, Evenity

  • DrugPlacebo

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Time to Radiographic Healing

    Time to radiographic healing was defined as the time from intramedullary (IM) nailing to the first occurrence of bridging of 3 out of 4 cortices. Radiographic fracture healing was determined by a panel of independent reviewers (orthopedic/trauma surgeons and radiologists) blinded to treatment. The cumulative incidence function (CIF) method was used to estimate the median time to radiographic healing and the confidence intervals. Unplanned revision surgery to promote healing was considered a competing risk in CIF estimate.

    Time frame: 52 weeks

Secondary outcomes

  1. Change From Week 8 in Short Form (36) Health Survey Physical Functioning Domain

    The Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2, is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical functioning domain includes 10 questions that assess limitations in physical activities because of health problems. Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. The range of SF-36 physical functioning is 14.94 - 57.03. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement in physical functioning.

    Time frame: Week 8 and weeks 12, 16, 20, 24, 36, and 52

  2. Number of Participants With Unplanned Revision Surgeries

    Time frame: 52 weeks

  3. Time to Clinical Healing

    Time to clinical healing was defined as the time from the IM nailing surgery date to the first date that both the score for ability to bear weight on the fractured limb and the score for absence of pain at the fracture site were equal to 6. The score for the ability to bear weight on the fractured limb was based on the ability to stand on affected leg without assistive device and the ability to walk without assistive device. The score ranges from 0 (unable to bear full body weight on the fractured limb) to 6 (able to bear full body weight on the fractured limb). Absence of pain at the fracture site was based on the absence of pain at the fracture site when applying direct pressure to the fracture site and applying a stress to the fracture site. The score ranges from 0 (pain without palpation at fracture site) to 6 (total absence of pain at fracture site). Time to clinical healing was estimated using CIF; unplanned revision surgery was considered a competing risk in CIF estimate.

    Time frame: 52 weeks

07

Results

Posted May 1, 2019

Participant flow

This study was conducted at 66 centers in Europe, India, North America, Australia, New Zealand, Hong Kong, and Mexico. Participants were enrolled from 02 September 2009 to 19 September 2011.

Participant flow — Overall Study
MilestonePlaceboRomosozumab 70 mg: 2 DosesRomosozumab 70 mg: 3 DosesRomosozumab 70 mg: 4 DosesRomosozumab 140 mg: 2 DosesRomosozumab 140 mg: 3 DosesRomosozumab 140 mg: 4 DosesRomosozumab 210 mg: 2 DosesRomosozumab 210 mg: 3 DosesRomosozumab 210 mg: 4 Doses
Started103343433333333333135
Received treatment100343432333231323035
Completed83293229322427262728
Not completed20524196747
Withdrew: Ineligibility determined1001000100
Withdrew: Protocol deviation0100000000
Withdrew: Noncompliance1110010200
Withdrew: Adverse event2000001001
Withdrew: Withdrawal by subject7211153242
Withdrew: Lost to follow-up9102032204

Outcome measures

PrimaryTime to Radiographic Healing

Time to radiographic healing was defined as the time from intramedullary (IM) nailing to the first occurrence of bridging of 3 out of 4 cortices. Radiographic fracture healing was determined by a panel of independent reviewers (orthopedic/trauma surgeons and radiologists) blinded to treatment. The cumulative incidence function (CIF) method was used to estimate the median time to radiographic healing and the confidence intervals. Unplanned revision surgery to promote healing was considered a competing risk in CIF estimate.

Time frame:
52 weeks
Reported as:
Median · weeks
Time to Radiographic Healing
weeksPlaceboRomosozumab 70 mg: 2 DosesRomosozumab 70 mg: 3 DosesRomosozumab 70 mg: 4 DosesRomosozumab 140 mg: 2 DosesRomosozumab 140 mg: 3 DosesRomosozumab 140 mg: 4 DosesRomosozumab 210 mg: 2 DosesRomosozumab 210 mg: 3 DosesRomosozumab 210 mg: 4 Doses
Time to Radiographic Healing16.4 (14.6 to 18.0)18.6 (14.0 to 24.4)18.3 (13.0 to 21.0)18.2 (13.7 to 20.7)17.8 (12.6 to 22.9)18.1 (13.1 to 20.7)17.0 (12.7 to 21.4)14.4 (12.6 to 17.0)15.4 (13.3 to 17.4)16.4 (14.4 to 18.6)
Statistical analysis
  • Placebo vs Romosozumab 70 mg: 2 Doses · Cox proportional hazard model · p = 0.3598 · Hazard ratio (hr): 0.82 · 95% CI 0.53 to 1.26A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 70 mg: 3 Doses · Cox proportional hazard model · p = 0.6544 · Hazard ratio (hr): 0.91 · 95% CI 0.59 to 1.39A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 70 mg: 4 Doses · Cox proportional hazard model · p = 0.9958 · Hazard ratio (hr): 1.00 · 95% CI 0.64 to 1.58A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 140 mg: 2 Doses · Cox proportional hazard model · p = 0.6276 · Hazard ratio (hr): 0.90 · 95% CI 0.59 to 1.37A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 140 mg: 3 Doses · Cox proportional hazard model · p = 0.8819 · Hazard ratio (hr): 0.97 · 95% CI 0.63 to 1.49A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 140 mg: 4 Doses · Cox proportional hazard model · p = 0.7197 · Hazard ratio (hr): 0.92 · 95% CI 0.60 to 1.42A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 210 mg: 2 Doses · Cox proportional hazard model · p = 0.6204 · Hazard ratio (hr): 1.11 · 95% CI 0.73 to 1.70A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 210 mg: 3 Doses · Cox proportional hazard model · p = 0.4779 · Hazard ratio (hr): 1.18 · 95% CI 0.75 to 1.84A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 210 mg: 4 Doses · Cox proportional hazard model · p = 0.9952 · Hazard ratio (hr): 1.00 · 95% CI 0.65 to 1.53A hazard ratio \> 1 favors romosozumab.
SecondaryChange From Week 8 in Short Form (36) Health Survey Physical Functioning Domain

The Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2, is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical functioning domain includes 10 questions that assess limitations in physical activities because of health problems. Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. The range of SF-36 physical functioning is 14.94 - 57.03. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement in physical functioning.

Time frame:
Week 8 and weeks 12, 16, 20, 24, 36, and 52
Reported as:
Mean · units on a scale
Change From Week 8 in Short Form (36) Health Survey Physical Functioning Domain
units on a scalePlaceboRomosozumab 70 mg: 2 DosesRomosozumab 70 mg: 3 DosesRomosozumab 70 mg: 4 DosesRomosozumab 140 mg: 2 DosesRomosozumab 140 mg: 3 DosesRomosozumab 140 mg: 4 DosesRomosozumab 210 mg: 2 DosesRomosozumab 210 mg: 3 DosesRomosozumab 210 mg: 4 Doses
Week 125.77 ± 9.906.31 ± 6.845.67 ± 8.605.04 ± 9.014.28 ± 8.227.08 ± 8.063.63 ± 9.303.65 ± 9.067.33 ± 7.995.64 ± 6.67
Week 169.64 ± 10.369.83 ± 7.249.19 ± 11.309.28 ± 11.148.89 ± 10.7111.18 ± 9.238.78 ± 11.349.23 ± 9.599.50 ± 9.019.01 ± 10.41
Week 2013.20 ± 12.2514.53 ± 9.6910.45 ± 11.6613.50 ± 12.0212.13 ± 10.8814.77 ± 13.5212.44 ± 11.9712.61 ± 10.8812.50 ± 10.7611.05 ± 11.56
Week 2415.87 ± 11.5515.07 ± 9.3110.34 ± 13.3115.90 ± 11.2614.57 ± 10.3416.84 ± 12.7011.79 ± 17.6413.05 ± 10.9913.05 ± 10.2512.38 ± 14.04
Week 3619.57 ± 11.6020.96 ± 11.6811.48 ± 17.8417.23 ± 10.1517.61 ± 11.0319.43 ± 12.8315.70 ± 19.0315.01 ± 11.2317.47 ± 14.3415.22 ± 15.20
Week 5220.74 ± 11.9623.47 ± 11.5513.63 ± 19.0419.02 ± 10.8019.63 ± 12.1724.80 ± 11.2417.19 ± 15.5115.50 ± 13.1718.29 ± 14.9415.44 ± 17.15
SecondaryNumber of Participants With Unplanned Revision Surgeries
Time frame:
52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Unplanned Revision Surgeries
ParticipantsPlaceboRomosozumab 70 mg: 2 DosesRomosozumab 70 mg: 3 DosesRomosozumab 70 mg: 4 DosesRomosozumab 140 mg: 2 DosesRomosozumab 140 mg: 3 DosesRomosozumab 140 mg: 4 DosesRomosozumab 210 mg: 2 DosesRomosozumab 210 mg: 3 DosesRomosozumab 210 mg: 4 Doses
Number of Participants With Unplanned Revision Surgeries8133100011
SecondaryTime to Clinical Healing

Time to clinical healing was defined as the time from the IM nailing surgery date to the first date that both the score for ability to bear weight on the fractured limb and the score for absence of pain at the fracture site were equal to 6. The score for the ability to bear weight on the fractured limb was based on the ability to stand on affected leg without assistive device and the ability to walk without assistive device. The score ranges from 0 (unable to bear full body weight on the fractured limb) to 6 (able to bear full body weight on the fractured limb). Absence of pain at the fracture site was based on the absence of pain at the fracture site when applying direct pressure to the fracture site and applying a stress to the fracture site. The score ranges from 0 (pain without palpation at fracture site) to 6 (total absence of pain at fracture site). Time to clinical healing was estimated using CIF; unplanned revision surgery was considered a competing risk in CIF estimate.

Time frame:
52 weeks
Reported as:
Median · weeks
Time to Clinical Healing
weeksPlaceboRomosozumab 70 mg: 2 DosesRomosozumab 70 mg: 3 DosesRomosozumab 70 mg: 4 DosesRomosozumab 140 mg: 2 DosesRomosozumab 140 mg: 3 DosesRomosozumab 140 mg: 4 DosesRomosozumab 210 mg: 2 DosesRomosozumab 210 mg: 3 DosesRomosozumab 210 mg: 4 Doses
Time to Clinical Healing18.4 (16.6 to 20.4)21.4 (15.7 to 28.6)18.3 (14.4 to 22.4)17.1 (14.4 to 21.0)20.8 (12.6 to 28.0)22.3 (15.0 to 24.3)15.0 (12.6 to 17.0)16.3 (12.4 to 21.0)14.6 (12.9 to 18.6)17.6 (14.9 to 19.7)
Statistical analysis
  • Placebo vs Romosozumab 70 mg: 2 Doses · Cox proportional hazard model · p = 0.1713 · Hazard ratio (hr): 0.73 · 95% CI 0.47 to 1.14A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 70 mg: 3 Doses · Cox proportional hazard model · p = 0.9958 · Hazard ratio (hr): 1.00 · 95% CI 0.65 to 1.53A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 70 mg: 4 Doses · Cox proportional hazard model · p = 0.2950 · Hazard ratio (hr): 1.27 · 95% CI 0.81 to 1.97A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 140 mg: 2 Doses · Cox proportional hazard model · p = 0.0844 · Hazard ratio (hr): 0.68 · 95% CI 0.44 to 1.05A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 140 mg: 3 Doses · Cox proportional hazard model · p = 0.3225 · Hazard ratio (hr): 0.80 · 95% CI 0.52 to 1.24A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 140 mg: 4 Doses · Cox proportional hazard model · p = 0.4754 · Hazard ratio (hr): 1.17 · 95% CI 0.76 to 1.81A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 210 mg: 2 Doses · Cox proportional hazard model · p = 0.5578 · Hazard ratio (hr): 1.14 · 95% CI 0.74 to 1.75A hazard ratio \> 1 favors romosozumab.
  • Placebo vs Romosozumab 210 mg: 3 Doses · Cox proportional hazard model · p = 0.1864 · Hazard ratio (hr): 1.34 · 95% CI 0.87 to 2.07A hazard ratio \> 1 favors romosozumab
  • Placebo vs Romosozumab 210 mg: 4 Doses · Cox proportional hazard model · p = 0.8488 · Hazard ratio (hr): 1.04 · 95% CI 0.68 to 1.59A hazard ratio \> 1 favors romosozumab.

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—10/100 (10%)38/100 (38%)
Romosozumab 70 mg: 2 Doses—4/34 (11.8%)9/34 (26.5%)
Romosozumab 70 mg: 3 Doses—2/34 (5.9%)17/34 (50%)
Romosozumab 70 mg: 4 Doses—3/32 (9.4%)12/32 (37.5%)
Romosozumab 140 mg: 2 Doses—3/33 (9.1%)16/33 (48.5%)
Romosozumab 140 mg: 3 Doses—4/32 (12.5%)7/32 (21.9%)
Romosozumab 140 mg: 4 Doses—2/31 (6.5%)9/31 (29%)
Romosozumab 210 mg: 2 Doses—3/32 (9.4%)10/32 (31.3%)
Romosozumab 210 mg: 3 Doses—3/30 (10%)9/30 (30%)
Romosozumab 210 mg: 4 Doses—0/35 (0%)6/35 (17.1%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventPlaceboRomosozumab 70 mg: 2 DosesRomosozumab 70 mg: 3 DosesRomosozumab 70 mg: 4 DosesRomosozumab 140 mg: 2 DosesRomosozumab 140 mg: 3 DosesRomosozumab 140 mg: 4 DosesRomosozumab 210 mg: 2 DosesRomosozumab 210 mg: 3 DosesRomosozumab 210 mg: 4 Doses
Device related infectionInfections and infestations1/1000/340/340/320/330/320/310/321/300/35
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/1000/340/340/320/330/320/310/321/300/35
Calculus uretericRenal and urinary disorders0/1000/340/340/320/330/320/310/321/300/35
Wound infectionInfections and infestations0/1000/340/340/320/331/321/310/320/300/35
Transient ischaemic attackNervous system disorders0/1000/340/340/320/330/321/310/320/300/35
InfectionInfections and infestations0/1000/341/340/320/331/320/310/320/300/35
MalariaInfections and infestations0/1000/340/340/320/331/320/310/320/300/35
Femur fractureInjury, poisoning and procedural complications1/1000/340/340/320/331/320/310/320/300/35
Fracture displacementInjury, poisoning and procedural complications0/1000/340/340/320/330/320/311/320/300/35
ExostosisMusculoskeletal and connective tissue disorders0/1000/340/340/320/330/320/311/320/300/35
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPlaceboRomosozumab 70 mg: 2 DosesRomosozumab 70 mg: 3 DosesRomosozumab 70 mg: 4 DosesRomosozumab 140 mg: 2 DosesRomosozumab 140 mg: 3 DosesRomosozumab 140 mg: 4 DosesRomosozumab 210 mg: 2 DosesRomosozumab 210 mg: 3 DosesRomosozumab 210 mg: 4 Doses
ArthralgiaMusculoskeletal and connective tissue disorders6/1001/341/345/324/333/320/314/322/302/35
Oedema peripheralGeneral disorders6/1000/344/344/323/332/321/313/322/301/35
Upper respiratory tract infectionInfections and infestations3/1001/344/340/320/331/320/311/320/300/35
DiarrhoeaGastrointestinal disorders2/1000/342/340/322/330/320/311/323/300/35
Pain in extremityMusculoskeletal and connective tissue disorders6/1000/340/340/321/332/323/311/321/300/35
Bone painMusculoskeletal and connective tissue disorders3/1001/340/343/321/331/320/310/322/300/35
PainGeneral disorders7/1000/342/341/321/331/321/310/320/301/35
VomitingGastrointestinal disorders4/1000/341/340/320/330/320/310/322/300/35
FallInjury, poisoning and procedural complications3/1000/340/341/321/331/320/310/322/300/35
Limb injuryInjury, poisoning and procedural complications0/1000/340/340/320/330/320/310/322/300/35

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboRomosozumab 70 mg: 2 DosesRomosozumab 70 mg: 3 DosesRomosozumab 70 mg: 4 DosesRomosozumab 140 mg: 2 DosesRomosozumab 140 mg: 3 DosesRomosozumab 140 mg: 4 DosesRomosozumab 210 mg: 2 DosesRomosozumab 210 mg: 3 DosesRomosozumab 210 mg: 4 DosesTotal
Mean40.3 ± 13.838.6 ± 13.843.2 ± 17.745.9 ± 15.641.3 ± 13.741.0 ± 14.938.7 ± 12.742.8 ± 13.736.8 ± 13.841.7 ± 14.440.9 ± 14.4
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRomosozumab 70 mg: 2 DosesRomosozumab 70 mg: 3 DosesRomosozumab 70 mg: 4 DosesRomosozumab 140 mg: 2 DosesRomosozumab 140 mg: 3 DosesRomosozumab 140 mg: 4 DosesRomosozumab 210 mg: 2 DosesRomosozumab 210 mg: 3 DosesRomosozumab 210 mg: 4 DosesTotal
Female2971088111151312114
Male74272425252222281823288
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRomosozumab 70 mg: 2 DosesRomosozumab 70 mg: 3 DosesRomosozumab 70 mg: 4 DosesRomosozumab 140 mg: 2 DosesRomosozumab 140 mg: 3 DosesRomosozumab 140 mg: 4 DosesRomosozumab 210 mg: 2 DosesRomosozumab 210 mg: 3 DosesRomosozumab 210 mg: 4 DosesTotal
White80202429222324252428299
Black or African American22101110008
Hispanic or Latino11011101118
Asian20119398876586
Other00000000011
Randomization Stratification
Randomization Stratification(Participants)PlaceboRomosozumab 70 mg: 2 DosesRomosozumab 70 mg: 3 DosesRomosozumab 70 mg: 4 DosesRomosozumab 140 mg: 2 DosesRomosozumab 140 mg: 3 DosesRomosozumab 140 mg: 4 DosesRomosozumab 210 mg: 2 DosesRomosozumab 210 mg: 3 DosesRomosozumab 210 mg: 4 DosesTotal
Closed with reamed IM nail88303029292929292829350
Gustilo type I/II open with reamed IM nail1034334443442
Gustilo type I/II open with unreamed IM nail510110000210
08

Study locations

103 sites
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Aurora, Colorado 80012, United States
  • Research Site
    Denver, Colorado 80204, United States
  • Research Site
    Jacksonville, Florida 32209, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Brooklyn, New York 11220, United States
  • Research Site
    Rochester, New York 14642, United States
  • Research Site
    Altoona, Pennsylvania 16602, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Columbia, South Carolina 29203, United States
  • Research Site
    Sandy, Utah 84070, United States
  • Research Site
    Geelong, Victoria 3220, Australia
  • Research Site
    Parkville, Victoria 3050, Australia
  • Research Site
    Blagoevgrad, 2700, Bulgaria
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Ruse, 7000, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Red Deer, Alberta T4N 6V7, Canada
  • Research Site
    Ajax, Ontario L1S 2J5, Canada
  • Research Site
    Thunder Bay, Ontario P7B 7C7, Canada
  • Research Site
    Toronto, Ontario M5C 1R6, Canada
  • Research Site
    Waterloo, Ontario N2J 1C4, Canada
  • Research Site
    Windsor, Ontario N9A 1E1, Canada
  • Research Site
    Montreal, Quebec H3G 1A4, Canada
  • Research Site
    Montreal, Quebec H4J 1C5, Canada
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    København NV, 2400, Denmark
  • Research Site
    Ã…rhus C, 8000, Denmark
  • Research Site
    Tallinn, 11312, Estonia
  • Research Site
    Tartu, 50410, Estonia
  • Research Site
    Lille, 59000, France
  • Research Site
    Marseille, 13009, France
  • Research Site
    Nantes Cedex 1, 44035, France
  • Research Site
    Paris Cedex 12, 75571, France
  • Research Site
    Aachen, 52074, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Hannover, 30625, Germany
  • Research Site
    Mannheim, 68165, Germany
  • Research Site
    Muenster, 48149, Germany
  • Research Site
    Athens, 12462, Greece
  • Research Site
    Athens, 14561, Greece
  • Research Site
    Larissa, 41110, Greece
  • Research Site
    Patra, 26500, Greece
  • Research Site
    Thessaloniki, 56429, Greece
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    New Territories, Hong Kong
  • Research Site
    Budapest, 1081, Hungary
  • Research Site
    Miskolc, 3526, Hungary
  • Research Site
    Nyiregyhaza, 4400, Hungary
  • Research Site
    Szeged, 6725, Hungary
  • Research Site
    Bangalore, Karnataka 560 034, India
  • Research Site
    Bangalore, Karnataka 560 054, India
  • Research Site
    Mangalore, Karnataka 575 002, India
  • Research Site
    Pune, Maharashtra 411 005, India
  • Research Site
    Jaipur, Rajasthan 302 022, India
  • Research Site
    Madurai, Tamil Nadu 625 020, India
  • Research Site
    Gandhinagar, 382 428, India
  • Research Site
    Mangalore, 575 001, India
  • Research Site
    Nashik, 422 009, India
  • Research Site
    Firenze, 50139, Italy
  • Research Site
    Milano, 20122, Italy
  • Research Site
    Milano, 20142, Italy
  • Research Site
    Pisa, 56126, Italy
  • Research Site
    Roma (RM), 00133, Italy
  • Research Site
    Verona, 37126, Italy
  • Research Site
    Liepaja, 3400, Latvia
  • Research Site
    Riga, 1004, Latvia
  • Research Site
    Riga, 1005, Latvia
  • Research Site
    Valmiera, 4201, Latvia
  • Research Site
    Kaunas, 44320, Lithuania
  • Research Site
    Vilnius, 04130, Lithuania
  • Research Site
    Monterrey, Nuevo León 64040, Mexico
  • Research Site
    Christchurch, 8022, New Zealand
  • Research Site
    Tauranga, 3143, New Zealand
  • Research Site
    Kongsvinger, 2226, Norway
  • Research Site
    Bialystok, 15-276, Poland
  • Research Site
    Bytom, 41-902, Poland
  • Research Site
    Krakow, 30-901, Poland
  • Research Site
    Kraków, 31-826, Poland
  • Research Site
    Lublin, 20-718, Poland
  • Research Site
    Bucharest, 014461, Romania
  • Research Site
    Bucuresti, 050098, Romania
  • Research Site
    Timisoara, 300736, Romania
  • Research Site
    Moscow, 115280, Russian Federation
  • Research Site
    Moscow, 117292, Russian Federation
  • Research Site
    Moscow, 119049, Russian Federation
  • Research Site
    Moscow, 127299, Russian Federation
  • Research Site
    Moscow, 129327, Russian Federation
  • Research Site
    Saint Petersburg, 196247, Russian Federation
  • Research Site
    Yaroslavl, 150003, Russian Federation
  • Research Site
    Bratislava, 833 05, Slovakia
  • Research Site
    Nitra, 950 01, Slovakia
  • Research Site
    Piestany, 921 01, Slovakia
  • Research Site
    Leeds, LS1 3EX, United Kingdom
  • Research Site
    London, E1 1BB, United Kingdom
  • Research Site
    Newcastle, NE1 4LP, United Kingdom

Showing the first 100 of 103 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bhandari M, Schemitsch EH, Karachalios T, Sancheti P, Poolman RW, Caminis J, Daizadeh N, Dent-Acosta RE, Egbuna O, Chines A, Miclau T. Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture: A Randomized Phase-2 Study. J Bone Joint Surg Am. 2020 Aug 19;102(16):1416-1426. doi: 10.2106/JBJS.19.01008. PubMed 32358413 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2009 to primary completion in Mar 2012, 30 months.

Results were first posted in May 2019, 7 years 1 month after primary completion. A results delay was requested in May 2013.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2009
First posted
May 22, 2009
StartActual
Sep 2, 2009
Primary completionActual
Mar 6, 2012
CompletionActual
May 10, 2013
Results delay requested
May 22, 2013
Results first posted
May 1, 2019
Last update
Sep 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00907296
Lead sponsor
Amgen
Collaborators
UCB Pharma
Responsible party
Sponsor
First posted
May 22, 2009
Start date
Sep 2, 2009
Primary completion
Mar 6, 2012
Completion
May 10, 2013
Results posted
May 1, 2019
Last update
Sep 22, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion